Extra research demonstrated that the axons in these mice acquired less myelination, recognized the biochemical pathway leading to these defects, referred to as the mTOR pathway, and demonstrated that the pathway and the myelination defects could possibly be reversed in mice with the mTOR-inhibiting medication rapamycin. Armed with one of these data, Sahin provides launched a Stage II medical trial of a rapamycin-like medication known as Afinitor – , sponsored by Novartis, the Tuberous Sclerosis Autism and Alliance Speaks.One study discovered that infant women are as apt to be infected seeing that infant boys twice. Both studies provide fresh details with which to counsel women that are pregnant infected with HCV. Taken together, the two new research expand upon preliminary data from smaller sized studies of mother-to-child transmission of HCV. The larger of the two research, carried out by the European Paediatric Hepatitis C Virus Network, involved 1,479 mother-and-child pairs enrolled at 33 centers in Italy, Spain, Germany, Ireland, the United Kingdom, Norway, and Sweden.